Please assess the completion status of the following clinical trial:

Trial Title: Once-daily Antiretroviral Therapy in HIV-1 Infected Patients With CD4+ Cell Counts Below 100 Cells/Mcl

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic HIV-1 infection~* Age 18 or more~* Antiretroviral-naive~* Baseline CD4+ count \<100 cels/mcL.~* No mutations of drug resistance at baseline (M184V/I, K65R, resistance to efavirenz or 2 or more PRAMs (L33I/F/V, V82A/F/L/T, I84V, L90M)~* Written informed consent~Exclusion Criteria:~* Hypersensibility to study drugs.~* Pregnancy or breastfeeding~* Active OI requiring admission~* Active lymphoma or malignancy (Kaposi sarcoma included)~* Cl creatinine below 30 ml/min.~* Liver failure~* Treatment with nephrotoxic drugs, immunomodulators, interleukine-2, systemic steroids or investigational products.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): tenofovir plus emtricitabine plus efavirenz
- 2 (Type: EXPERIMENTAL): tenofovir plus emtricitabine plus lopinavir-ritonavir
- 3 (Type: EXPERIMENTAL): tenofovir plus emtricitabine plus atazanavir-ritonavir

Based on this trial design, predict the completion outcome and termination type (if applicable).